101875-03-0

Basic information

• Product Name: 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-pyrimidin-2-yl benzenesulfonamide
• Synonyms: 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-pyrimidin-2-yl benzenesulfonamide
• CAS NO: 101875-03-0
• Molecular Weight: 380.384
• Mol File: 101875-03-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-pyrimidin-2-yl benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-pyrimidin-2-yl benzenesulfonamide(101875-03-0)
• EPA Substance Registry System: 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-pyrimidin-2-yl benzenesulfonamide(101875-03-0)

Safety Data

• Hazardous Substances Data: 101875-03-0(Hazardous Substances Data)

Upstream product

• 68-35-9 sulfadiazine 
• 88-99-3 benzene-1,2-dicarboxylic acid 
• 85-44-9 phthalic anhydride 

Relevant articles and documents

Some studies in sulfadiazine incorporating pyridine, pyrimidine, oxadiazole, and azo moieties endowed with pharmaceutical potency

A set of substituted sulfadiazine compounds was prepared as cytotoxic and antitumor agents by using 4-amino-N-(py-rimidin-2-yl)benzenesulfonamide (1) as the starting material. Compound 1 was reacted with different reagents to give the corresponding sulfadiazines 2-18 and hydrozaones 19a-h which were evaluated for their in vitro cytotoxicity versus four cancer cell lines. Compounds 3, 5, 19d and 19h were active against the tested cancer cells.

Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions

We synthesized a series of novel dapsone-thalidomide hybrids (3a-i) by molecular hybridization and evaluated their potential for the treatment of type 2 leprosy reactions. All of the compounds had analgesic properties. Compounds 3c and 3h were the most active antinociceptive compounds and reduced acetic acid-induced abdominal constrictions by 49.8% and 39.1%, respectively. The hybrid compounds also reduced tumor necrosis factor-α levels in lipopolysaccharide-stimulated L929 cells. Compound 3i was the most active compound; at concentrations of 15.62 and 125 μM, compound 3i decreased tumor necrosis factor-α levels by 86.33% and 87.80%, respectively. In nude mice infected with Mycobacterium leprae in vivo, compound 3i did not reduce the number of bacilli compared with controls. Compound 3i did not have mutagenic effects in Salmonella typhimurium strains TA100 and TA102, with or without metabolic activation (S9 mixture). Our results indicate that compound 3i is a novel lead compound for the treatment of type 2 leprosy reactions.